title: Simultaneous appearance of central nervous system relapse and subarachnoid hemorrhage during the treatment for acute promyelocytic leukemia.
authors.forename: Sumimasa
authors.initials: S
authors.lastname: Nagai
authors.forename: Takashi
authors.initials: T
authors.lastname: Asai
authors.forename: Takuro
authors.initials: T
authors.lastname: Watanabe
authors.forename: Kumi
authors.initials: K
authors.lastname: Oshima
authors.forename: Akira
authors.initials: A
authors.lastname: Hangaishi
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Kanda
authors.forename: Toru
authors.initials: T
authors.lastname: Motokura
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
authors.forename: Shigeki
authors.initials: S
authors.lastname: Aoki
authors.forename: Kuni
authors.initials: K
authors.lastname: Ohtomo
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D000293:Adolescent; D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004730:Endothelium, Vascular / Q000187:drug effects; D000079982:Gemtuzumab; D006801:Humans; D007278:Injections, Spinal; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D017254:Leukemic Infiltration; D008279:Magnetic Resonance Imaging; D008297:Male; D008578:Meninges / Q000473:pathology*; D008875:Middle Aged; D010087:Oxides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000209:etiology; D012008:Recurrence; D013345:Subarachnoid Hemorrhage / Q000000981:diagnostic imaging / Q000209:etiology*; D014057:Tomography, X-Ray Computed
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D000079982:Gemtuzumab; D000077237:Arsenic Trioxide